HONG KONG – Jiangsu Hengrui Medicine Co. Ltd. said the China National Drug Administration (CNDA) granted a conditional approval to its self-developed compound pyrotinib for treating HER2-positive breast cancer. The approval was based on clinical data from phase II studies, demonstrating China's effort in marketing domestic innovative drugs faster.
HONG KONG – Canbridge Life Sciences Ltd., of Beijing, said it would soon initiate a phase Ib/III clinical study of its monoclonal antibody candidate CAN-017 in esophageal squamous cell cancer (ESCC). The multicenter study will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of CAN-017 in combination with chemotherapy as the second-line treatment for patients with locally advanced or metastatic ESCC.
HONG KONG – In late May, the China National Drug Administration (CNDA), along with four other bodies, published the list of rare diseases that includes 121 indications, with the aim of encouraging research and development of orphan drugs and speeding up their marketing in China, all the while making those drugs more affordable for patients.
HONG KONG – Chinese biopharma Impact Therapeutics Inc., of Nanjing, has received $30 million in series C financing to advance the clinical development of its lead candidate, IMP-4297, a PARP inhibitor, to treat multiple tumors.
HONG KONG – Chinese biopharma Impact Therapeutics Inc., of Nanjing, has received $30 million in series C financing to advance the clinical development of its lead candidate, IMP-4297, a PARP inhibitor, to treat multiple tumors.
HONG KONG – In late May, the China National Drug Administration (CNDA), along with four other bodies, published the list of rare diseases that includes 121 indications, with the aim of encouraging research and development of orphan drugs and speeding up their marketing in China, all the while making those drugs more affordable for patients.
HONG KONG – Chinese firm Cure Genetics Co. Ltd., of Suzhou, has secured $17 million in series A financing to advance its gene-editing and delivery platform to treat easy-to-relapse or hard-to-treat cancers and genetic diseases.
